Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:53
05/23/22
05/23
09:53
05/23/22
09:53
ANF

Abercrombie & Fitch

$26.61 /

-1.38 (-4.93%)

, FTCI

FTC Solar

$3.65 /

-0.185 (-4.82%)

, ARRY

Array Technologies

$8.82 /

-0.255 (-2.81%)

, APLD

Applied Blockchain

$3.73 /

+0.095 (+2.61%)

, WAB

Wabtec

$88.27 /

+1.265 (+1.45%)

, RDUS

Radius Health

$6.24 /

-0.005 (-0.08%)

, AMGN

Amgen

$248.83 /

+1.31 (+0.53%)

, HZNP

Horizon Therapeutics

$88.88 /

-1.44 (-1.59%)

, GILD

Gilead

$64.37 /

+0.525 (+0.82%)

, VRTX

Vertex Pharmaceuticals

$260.33 /

+1.51 (+0.58%)

, PFE

Pfizer

$53.19 /

+0.715 (+1.36%)

, ROIV

Roivant Sciences

$3.85 /

+0.13 (+3.49%)

, SNY

Sanofi

$54.94 /

+0.56 (+1.03%)

, REGN

Regeneron

$671.89 /

+12.36 (+1.87%)

, LLY

Eli Lilly

$301.34 /

+2.43 (+0.81%)

, ABBV

AbbVie

$150.50 /

-0.54 (-0.36%)

, FTDR

Frontdoor

$25.71 /

-0.735 (-2.78%)

, ATHX

Athersys

/

+

, HPQ

HP Inc.

$34.48 /

-0.18 (-0.52%)

, ADSK

Autodesk

$178.14 /

-13.36 (-6.98%)

, CRI

Carter's

$73.96 /

-1.53 (-2.03%)

, PLCE

Children's Place

$42.40 /

-3.22 (-7.06%)

, AEO

American Eagle

$12.86 /

-0.46 (-3.45%)

, KSS

Kohl's

$37.69 /

-1.49 (-3.80%)

, RL

Ralph Lauren

$93.00 /

-0.24 (-0.26%)

, UAA

Under Armour

$9.51 /

-0.12 (-1.25%)

, UA

Under Armour

$8.39 /

-0.08 (-0.94%)

, MSI

Motorola Solutions

$213.79 /

+3.42 (+1.63%)

, THS

TreeHouse

$39.60 /

+2.905 (+7.92%)

, ZBRA

Zebra Technologies

$327.83 /

+2.41 (+0.74%)

, CUBE

CubeSmart

$42.15 /

+1.3 (+3.18%)

, SAIA

Saia

$195.00 /

+7.82 (+4.18%)

, GPS

Gap

$10.47 /

-0.46 (-4.21%)

Institutional investors…

ShowHide Related Items >><<
ZBRA Zebra Technologies
$327.83 /

+2.41 (+0.74%)

WAB Wabtec
$88.27 /

+1.265 (+1.45%)

VRTX Vertex Pharmaceuticals
$260.33 /

+1.51 (+0.58%)

UAA Under Armour
$9.51 /

-0.12 (-1.25%)

UA Under Armour
$8.39 /

-0.08 (-0.94%)

THS TreeHouse
$39.60 /

+2.905 (+7.92%)

SNY Sanofi
$54.94 /

+0.56 (+1.03%)

SAIA Saia
$195.00 /

+7.82 (+4.18%)

ROIV Roivant Sciences
$3.85 /

+0.13 (+3.49%)

RL Ralph Lauren
$93.00 /

-0.24 (-0.26%)

REGN Regeneron
$671.89 /

+12.36 (+1.87%)

RDUS Radius Health
$6.24 /

-0.005 (-0.08%)

PLCE Children's Place
$42.40 /

-3.22 (-7.06%)

PFE Pfizer
$53.19 /

+0.715 (+1.36%)

MSI Motorola Solutions
$213.79 /

+3.42 (+1.63%)

LLY Eli Lilly
$301.34 /

+2.43 (+0.81%)

KSS Kohl's
$37.69 /

-1.49 (-3.80%)

HZNP Horizon Therapeutics
$88.88 /

-1.44 (-1.59%)

HPQ HP Inc.
$34.48 /

-0.18 (-0.52%)

GPS Gap
$10.47 /

-0.46 (-4.21%)

GILD Gilead
$64.37 /

+0.525 (+0.82%)

FTDR Frontdoor
$25.71 /

-0.735 (-2.78%)

FTCI FTC Solar
$3.65 /

-0.185 (-4.82%)

CRI Carter's
$73.96 /

-1.53 (-2.03%)

ATHX Athersys
/

+

ARRY Array Technologies
$8.82 /

-0.255 (-2.81%)

APLD Applied Blockchain
$3.73 /

+0.095 (+2.61%)

ANF Abercrombie & Fitch
$26.61 /

-1.38 (-4.93%)

AMGN Amgen
$248.83 /

+1.31 (+0.53%)

AEO American Eagle
$12.86 /

-0.46 (-3.45%)

ADSK Autodesk
$178.14 /

-13.36 (-6.98%)

ABBV AbbVie
$150.50 /

-0.54 (-0.36%)

ANF Abercrombie & Fitch
$26.61 /

-1.38 (-4.93%)

05/23/22 Citi
Abercrombie & Fitch downgraded to Neutral from Buy at Citi
05/16/22 JPMorgan
Abercrombie & Fitch price target raised to $39 from $35 at JPMorgan
04/11/22 JPMorgan
Abercrombie & Fitch price target lowered to $35 from $41 at JPMorgan
03/16/22 B. Riley
B. Riley says teen/young adult apparel 'poised for a breakout'
FTCI FTC Solar
$3.65 /

-0.185 (-4.82%)

05/23/22 Northland
FTC Solar initiated with an Outperform at Northland
05/11/22 Cowen
FTC Solar price target lowered to $6 from $10 at Cowen
05/10/22 Raymond James
FTC Solar price target lowered to $7 from $10 at Raymond James
04/21/22 Piper Sandler
FTC Solar downgraded to sell on likely guidance cut at Piper Sandler
ARRY Array Technologies
$8.82 /

-0.255 (-2.81%)

05/23/22 Northland
Array Technologies initiated with an Outperform at Northland
05/12/22 Truist
Array Technologies price target lowered to $8 from $14 at Truist
05/11/22 Roth Capital
Array Technologies downgraded to Neutral from Buy at Roth Capital
APLD Applied Blockchain
$3.73 /

+0.095 (+2.61%)

05/23/22 Craig-Hallum
Craig-Hallum bullish on Applied Blockchain, initiates with a Buy
05/23/22 Craig-Hallum
Applied Blockchain initiated with a Buy at Craig-Hallum
05/09/22 Lake Street
Applied Blockchain initiated with a Buy at Lake Street
05/09/22 Northland
Applied Blockchain initiated with an Outperform at Northland
WAB Wabtec
$88.27 /

+1.265 (+1.45%)

05/23/22 Atlantic Equities
Wabtec initiated with Overweight, $101 target at Atlantic Equities
05/23/22 Atlantic Equities
Wabtec initiated with an Overweight at Atlantic Equities
04/28/22 Wolfe Research
Wabtec upgraded to Peer Perform from Underperform at Wolfe Research
01/10/22 Wells Fargo
Wabtec price target raised to $110 from $105 at Wells Fargo
RDUS Radius Health
$6.24 /

-0.005 (-0.08%)

05/23/22 SVB Leerink
Radius Health initiated with a Market Perform at SVB Leerink
12/23/21 Stifel
New Radius' Tymlos label offers slight expansion potential, says Stifel
12/10/21 Morgan Stanley
Radius Health downgraded to Underweight from Equal Weight at Morgan Stanley
12/09/21 Goldman Sachs
Radius Health downgraded to Neutral from Buy at Goldman Sachs
AMGN Amgen
$248.83 /

+1.31 (+0.53%)

05/23/22 SVB Leerink
Amgen initiated with a Market Perform at SVB Leerink
05/10/22 Mizuho
Amgen price target raised to $208 from $202 at Mizuho
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
HZNP Horizon Therapeutics
$88.88 /

-1.44 (-1.59%)

05/23/22 SVB Leerink
Horizon Therapeutics initiated with a Market Perform at SVB Leerink
03/14/22 Oppenheimer
Horizon Therapeutics initiated with an Outperform at Oppenheimer
01/26/22 Piper Sandler
Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
01/18/22 JPMorgan
Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
GILD Gilead
$64.37 /

+0.525 (+0.82%)

05/23/22 SVB Leerink
Gilead initiated with a Market Perform at SVB Leerink
05/17/22 BMO Capital
Scholar Rock price target lowered to $55 from $74 at BMO Capital
05/16/22 Piper Sandler
Gilead price target lowered to $69 from $73 at Piper Sandler
04/29/22 Piper Sandler
Gilead price target raised to $73 from $72 at Piper Sandler
VRTX Vertex Pharmaceuticals
$260.33 /

+1.51 (+0.58%)

05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
05/23/22 SVB Leerink
Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
05/06/22 Wells Fargo
Vertex Pharmaceuticals price target raised to $305 from $300 at Wells Fargo
05/06/22 Baird
Vertex Pharmaceuticals downgraded to Neutral at Baird after 21% advance
PFE Pfizer
$53.19 /

+0.715 (+1.36%)

05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
05/23/22 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
ROIV Roivant Sciences
$3.85 /

+0.13 (+3.49%)

05/23/22 SVB Leerink
Roivant Sciences initiated with an Outperform at SVB Leerink
04/29/22 Cantor Fitzgerald
Roivant Sciences initiated with an Overweight at Cantor Fitzgerald
12/15/21 Goldman Sachs
Roivant Sciences initiated with a Buy at Goldman Sachs
12/02/21 H.C. Wainwright
H.C. Wainwright says Arbutus patent win may mean 'considerable gain' for Roivant
SNY Sanofi
$54.94 /

+0.56 (+1.03%)

05/23/22 SVB Leerink
Sanofi initiated with an Outperform at SVB Leerink
05/09/22 Wedbush
Wedbush downgrades Arvinas to Neutral, cuts price target to $43
05/02/22 Guggenheim
Sanofi price target raised to EUR 127 from EUR 121 at Guggenheim
04/28/22 Credit Suisse
Kymera Therapeutics initiated with an Outperform at Credit Suisse
REGN Regeneron
$671.89 /

+12.36 (+1.87%)

05/23/22 SVB Leerink
Regeneron initiated with an Outperform at SVB Leerink
05/13/22 Piper Sandler
Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler
04/20/22 Cowen
Regeneron price target raised to $645 from $640 at Cowen
04/20/22 BTIG
Checkmate Pharmaceuticals downgraded to Neutral from Buy at BTIG
LLY Eli Lilly
$301.34 /

+2.43 (+0.81%)

05/23/22 SVB Leerink
Eli Lilly initiated with an Outperform at SVB Leerink
05/02/22 Wells Fargo
AbbVie price target raised to $200 from $165 at Wells Fargo
05/02/22 Mizuho
Eli Lilly price target raised to $356 from $315 at Mizuho
04/29/22 Morgan Stanley
Eli Lilly price target raised to $369 from $364 at Morgan Stanley
ABBV AbbVie
$150.50 /

-0.54 (-0.36%)

05/23/22 SVB Leerink
AbbVie initiated with an Underperform at SVB Leerink
05/06/22 Daiwa
AbbVie downgraded to Neutral from Outperform at Daiwa
05/03/22 Morgan Stanley
Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure
FTDR Frontdoor
$25.71 /

-0.735 (-2.78%)

05/23/22 Truist
Frontdoor downgraded to Hold at Truist on leadership transition
05/23/22 Truist
Frontdoor downgraded to Hold from Buy at Truist
05/06/22 Truist
Frontdoor price target lowered to $32 from $50 at Truist
05/06/22 Raymond James
Frontdoor price target lowered to $31 from $40 at Raymond James
ATHX Athersys
/

+

05/23/22 BofA
Athersys downgraded to Underperform from Neutral at BofA
11/19/21 BofA
Athersys downgraded to Neutral from Buy at BofA (yesterday)
HPQ HP Inc.
$34.48 /

-0.18 (-0.52%)

05/23/22 Citi
HP Inc. downgraded to Neutral from Buy at Citi
05/18/22 Jefferies
Information Technology sector upgraded to Bullish at Jefferies
05/16/22 Evercore ISI
HP Inc. added to 'Tactical Outperform' list at Evercore ISI
04/08/22 UBS
HP Inc. downgraded to Neutral from Buy at UBS
ADSK Autodesk
$178.14 /

-13.36 (-6.98%)

05/23/22 Stifel
Autodesk price target lowered to $230 from $285 at Stifel
05/23/22 RBC Capital
Autodesk price target lowered to $255 from $295 at RBC Capital
05/23/22 Deutsche Bank
Deutsche Bank downgrades Autodesk on risk to consensus estimates
05/23/22 Deutsche Bank
Autodesk downgraded to Hold from Buy at Deutsche Bank
CRI Carter's
$73.96 /

-1.53 (-2.03%)

05/23/22 Citi
Carter's downgraded to Sell from Buy at Citi
04/27/22 BofA
Carter's downgraded to Underperform from Buy at BofA
04/05/22 Wells Fargo
Carter's price target lowered to $95 from $105 at Wells Fargo
03/07/22 Wedbush
Carter's upgraded to Outperform from Neutral at Wedbush
PLCE Children's Place
$42.40 /

-3.22 (-7.06%)

05/23/22 Citi
Children's Place downgraded to Sell from Neutral at Citi
05/20/22 Citi
Children's Place price target lowered to $48 from $60 at Citi
05/17/22 B. Riley
Children's Place price target lowered to $84 from $105 at B. Riley
03/23/22 UBS
Children's Place price target lowered to $60 from $85 at UBS
AEO American Eagle
$12.86 /

-0.46 (-3.45%)

05/23/22 Citi
American Eagle downgraded to Neutral from Buy at Citi
05/17/22 B. Riley
American Eagle price target lowered to $32 from $41 at B. Riley
05/16/22 JPMorgan
American Eagle price target lowered to $20 from $29 at JPMorgan
04/11/22 JPMorgan
American Eagle price target lowered to $29 from $32 at JPMorgan
KSS Kohl's
$37.69 /

-1.49 (-3.80%)

05/23/22 Citi
Kohl's downgraded to Neutral from Buy at Citi
05/20/22 Morgan Stanley
Kohl's price target lowered to $38 from $42 at Morgan Stanley
05/20/22 Cowen
Kohl's price target lowered to $60 from $75 at Cowen
05/20/22 Deutsche Bank
Kohl's price target lowered to $68 from $85 at Deutsche Bank
RL Ralph Lauren
$93.00 /

-0.24 (-0.26%)

05/23/22 Citi
Ralph Lauren downgraded to Neutral from Buy at Citi
05/18/22 Credit Suisse
Ralph Lauren price target lowered to $130 from $165 at Credit Suisse
05/16/22 Deutsche Bank
Ralph Lauren price target lowered to $116 from $136 at Deutsche Bank
04/05/22 Wells Fargo
Ralph Lauren downgraded to Equal Weight from Overweight at Wells Fargo
UAA Under Armour
$9.51 /

-0.12 (-1.25%)

05/23/22 Citi
Under Armour downgraded to Neutral from Buy at Citi
05/19/22 Williams Trading
Under Armour downgraded to Hold from Buy at Williams Trading
05/19/22 Morgan Stanley
Under Armour downgraded to Equal Weight from Overweight at Morgan Stanley
05/11/22 Argus
Under Armour price target lowered to $15 from $19 at Argus
UA Under Armour
$8.39 /

-0.08 (-0.94%)

05/10/22 Barclays
Under Armour price target lowered to $14 from $22 at Barclays
05/09/22 B. Riley
Under Armour price target lowered to $11 from $18 at B. Riley
MSI Motorola Solutions
$213.79 /

+3.42 (+1.63%)

05/23/22 Morgan Stanley
Motorola Solutions assumed at Overweight from Equal Weight at Morgan Stanley
05/09/22 Credit Suisse
Credit Suisse starts Axon at Outperform with $169 price target
05/09/22 Credit Suisse
Credit Suisse starts Tyler Technologies at Neutral with $408 price target
04/25/22 Loop Capital
Motorola Solutions initiated with a Buy at Loop Capital
THS TreeHouse
$39.60 /

+2.905 (+7.92%)

05/23/22 Truist
TreeHouse upgraded to Buy from Hold at Truist
05/23/22 Truist
TreeHouse upgraded to Buy from Hold at Truist
03/22/22 Truist
TreeHouse price target lowered to $35 from $40 at Truist
ZBRA Zebra Technologies
$327.83 /

+2.41 (+0.74%)

05/23/22 Morgan Stanley
Zebra Technologies assumed at Equal Weight from Underweight at Morgan Stanley
05/04/22 Needham
Zebra Technologies price target lowered to $500 from $535 at Needham
05/04/22 Baird
Zebra Technologies price target lowered to $440 from $550 at Baird
04/12/22 Morgan Stanley
Morgan Stanley cuts Telecom & Networking Equipment industry view to Cautious
CUBE CubeSmart
$42.15 /

+1.3 (+3.18%)

05/23/22 Raymond James
CubeSmart upgraded to Strong Buy from Outperform at Raymond James
05/23/22 Raymond James
CubeSmart upgraded to Strong Buy from Outperform at Raymond James
05/16/22 Truist
CubeSmart price target lowered to $48 from $55 at Truist
04/04/22 JPMorgan
CubeSmart price target raised to $58 from $57 at JPMorgan
SAIA Saia
$195.00 /

+7.82 (+4.18%)

05/23/22 UBS
Saia upgraded to Buy from Neutral at UBS
05/19/22 Citi
Saia price target lowered to $190 from $230 at Citi
05/03/22 Wells Fargo
Saia price target raised to $290 from $273 at Wells Fargo
04/20/22 Raymond James
Saia price target lowered to $275 from $350 at Raymond James
GPS Gap
$10.47 /

-0.46 (-4.21%)

05/23/22 Citi
Gap downgraded to Sell from Neutral at Citi
05/17/22 UBS
Gap price target lowered to $14 from $18 at UBS
05/16/22 JPMorgan
Gap price target lowered to $11 from $14 at JPMorgan
04/25/22 Guggenheim
Guggenheim upgrades Gap to Buy with shares 70% off highs
ZBRA Zebra Technologies
$327.83 /

+2.41 (+0.74%)

WAB Wabtec
$88.27 /

+1.265 (+1.45%)

VRTX Vertex Pharmaceuticals
$260.33 /

+1.51 (+0.58%)

UAA Under Armour
$9.51 /

-0.12 (-1.25%)

THS TreeHouse
$39.60 /

+2.905 (+7.92%)

SNY Sanofi
$54.94 /

+0.56 (+1.03%)

SAIA Saia
$195.00 /

+7.82 (+4.18%)

ROIV Roivant Sciences
$3.85 /

+0.13 (+3.49%)

RL Ralph Lauren
$93.00 /

-0.24 (-0.26%)

REGN Regeneron
$671.89 /

+12.36 (+1.87%)

RDUS Radius Health
$6.24 /

-0.005 (-0.08%)

PLCE Children's Place
$42.40 /

-3.22 (-7.06%)

PFE Pfizer
$53.19 /

+0.715 (+1.36%)

MSI Motorola Solutions
$213.79 /

+3.42 (+1.63%)

LLY Eli Lilly
$301.34 /

+2.43 (+0.81%)

KSS Kohl's
$37.69 /

-1.49 (-3.80%)

HZNP Horizon Therapeutics
$88.88 /

-1.44 (-1.59%)

HPQ HP Inc.
$34.48 /

-0.18 (-0.52%)

GPS Gap
$10.47 /

-0.46 (-4.21%)

GILD Gilead
$64.37 /

+0.525 (+0.82%)

FTDR Frontdoor
$25.71 /

-0.735 (-2.78%)

FTCI FTC Solar
$3.65 /

-0.185 (-4.82%)

CUBE CubeSmart
$42.15 /

+1.3 (+3.18%)

CRI Carter's
$73.96 /

-1.53 (-2.03%)

ATHX Athersys
/

+

ARRY Array Technologies
$8.82 /

-0.255 (-2.81%)

ANF Abercrombie & Fitch
$26.61 /

-1.38 (-4.93%)

AMGN Amgen
$248.83 /

+1.31 (+0.53%)

AEO American Eagle
$12.86 /

-0.46 (-3.45%)

ADSK Autodesk
$178.14 /

-13.36 (-6.98%)

ABBV AbbVie
$150.50 /

-0.54 (-0.36%)

  • 13
    Apr
  • 17
    Nov
VRTX Vertex Pharmaceuticals
$260.33 /

+1.51 (+0.58%)

UAA Under Armour
$9.51 /

-0.12 (-1.25%)

SNY Sanofi
$54.94 /

+0.56 (+1.03%)

RL Ralph Lauren
$93.00 /

-0.24 (-0.26%)

REGN Regeneron
$671.89 /

+12.36 (+1.87%)

PFE Pfizer
$53.19 /

+0.715 (+1.36%)

LLY Eli Lilly
$301.34 /

+2.43 (+0.81%)

KSS Kohl's
$37.69 /

-1.49 (-3.80%)

HPQ HP Inc.
$34.48 /

-0.18 (-0.52%)

GPS Gap
$10.47 /

-0.46 (-4.21%)

GILD Gilead
$64.37 /

+0.525 (+0.82%)

FTCI FTC Solar
$3.65 /

-0.185 (-4.82%)

AMGN Amgen
$248.83 /

+1.31 (+0.53%)

ABBV AbbVie
$150.50 /

-0.54 (-0.36%)

ZBRA Zebra Technologies
$327.83 /

+2.41 (+0.74%)

WAB Wabtec
$88.27 /

+1.265 (+1.45%)

VRTX Vertex Pharmaceuticals
$260.33 /

+1.51 (+0.58%)

UAA Under Armour
$9.51 /

-0.12 (-1.25%)

THS TreeHouse
$39.60 /

+2.905 (+7.92%)

SNY Sanofi
$54.94 /

+0.56 (+1.03%)

SAIA Saia
$195.00 /

+7.82 (+4.18%)

ROIV Roivant Sciences
$3.85 /

+0.13 (+3.49%)

RL Ralph Lauren
$93.00 /

-0.24 (-0.26%)

REGN Regeneron
$671.89 /

+12.36 (+1.87%)

RDUS Radius Health
$6.24 /

-0.005 (-0.08%)

PLCE Children's Place
$42.40 /

-3.22 (-7.06%)

PFE Pfizer
$53.19 /

+0.715 (+1.36%)

MSI Motorola Solutions
$213.79 /

+3.42 (+1.63%)

LLY Eli Lilly
$301.34 /

+2.43 (+0.81%)

KSS Kohl's
$37.69 /

-1.49 (-3.80%)

HZNP Horizon Therapeutics
$88.88 /

-1.44 (-1.59%)

HPQ HP Inc.
$34.48 /

-0.18 (-0.52%)

GPS Gap
$10.47 /

-0.46 (-4.21%)

GILD Gilead
$64.37 /

+0.525 (+0.82%)

FTCI FTC Solar
$3.65 /

-0.185 (-4.82%)

CRI Carter's
$73.96 /

-1.53 (-2.03%)

ARRY Array Technologies
$8.82 /

-0.255 (-2.81%)

APLD Applied Blockchain
$3.73 /

+0.095 (+2.61%)

ANF Abercrombie & Fitch
$26.61 /

-1.38 (-4.93%)

AMGN Amgen
$248.83 /

+1.31 (+0.53%)

AEO American Eagle
$12.86 /

-0.46 (-3.45%)

ADSK Autodesk
$178.14 /

-13.36 (-6.98%)

ABBV AbbVie
$150.50 /

-0.54 (-0.36%)

ZBRA Zebra Technologies
$327.83 /

+2.41 (+0.74%)

VRTX Vertex Pharmaceuticals
$260.33 /

+1.51 (+0.58%)

UAA Under Armour
$9.51 /

-0.12 (-1.25%)

UA Under Armour
$8.39 /

-0.08 (-0.94%)

ROIV Roivant Sciences
$3.85 /

+0.13 (+3.49%)

RL Ralph Lauren
$93.00 /

-0.24 (-0.26%)

RDUS Radius Health
$6.24 /

-0.005 (-0.08%)

PFE Pfizer
$53.19 /

+0.715 (+1.36%)

LLY Eli Lilly
$301.34 /

+2.43 (+0.81%)

KSS Kohl's
$37.69 /

-1.49 (-3.80%)

HPQ HP Inc.
$34.48 /

-0.18 (-0.52%)

GPS Gap
$10.47 /

-0.46 (-4.21%)

GILD Gilead
$64.37 /

+0.525 (+0.82%)

FTCI FTC Solar
$3.65 /

-0.185 (-4.82%)

ATHX Athersys
/

+

ARRY Array Technologies
$8.82 /

-0.255 (-2.81%)

AMGN Amgen
$248.83 /

+1.31 (+0.53%)

AEO American Eagle
$12.86 /

-0.46 (-3.45%)

ADSK Autodesk
$178.14 /

-13.36 (-6.98%)

ABBV AbbVie
$150.50 /

-0.54 (-0.36%)

Hot Stocks
Insmed names Drayton Wise as Chief Commercial Officer » 08:03
05/23/22
05/23
08:03
05/23/22
08:03
INSM

Insmed

$20.27 /

+0.69 (+3.52%)

, NVS

Novartis

$89.43 /

+0.72 (+0.81%)

Insmed (INSM) announced…

Insmed (INSM) announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23. In addition to his current responsibilities leading the global ARIKAYCE franchise and U.S. commercial activities, Wise will assume responsibility for all of Insmed's global commercial functions. Wise will also serve as a member of Insmed's Executive Committee. Wise joined Insmed in 2014, holding positions of increasing responsibility in the Commercial organization and most recently serving as Senior Vice President, Head of U.S., and General Manager of ARIKAYCE. Prior to Insmed, he held various sales and commercial roles at Novartis (NVS) from 1999 to 2014.

ShowHide Related Items >><<
NVS Novartis
$89.43 /

+0.72 (+0.81%)

INSM Insmed
$20.27 /

+0.69 (+3.52%)

INSM Insmed
$20.27 /

+0.69 (+3.52%)

04/27/22 Goldman Sachs
Insmed initiated with a Buy at Goldman Sachs
12/06/21 JPMorgan
Insmed initiated with an Overweight at JPMorgan
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
10/19/21 Morgan Stanley
Insmed assumed with an Overweight at Morgan Stanley
NVS Novartis
$89.43 /

+0.72 (+0.81%)

05/13/22 Piper Sandler
Point Biopharma price target lowered to $14 from $17 at Piper Sandler
05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
05/09/22 Wolfe Research
Novartis downgraded to Peer Perform from Outperform at Wolfe Research
05/06/22 Morgan Stanley
Novartis price target raised to CHF 94 from CHF 90 at Morgan Stanley
NVS Novartis
$89.43 /

+0.72 (+0.81%)

INSM Insmed
$20.27 /

+0.69 (+3.52%)

NVS Novartis
$89.43 /

+0.72 (+0.81%)

NVS Novartis
$89.43 /

+0.72 (+0.81%)

Initiation
Radius Health initiated with a Market Perform at SVB Leerink » 06:40
05/23/22
05/23
06:40
05/23/22
06:40
RDUS

Radius Health

$6.25 /

+0.41 (+7.03%)

, AMGN

Amgen

$247.42 /

+2.48 (+1.01%)

SVB Leerink analyst David…

SVB Leerink analyst David Risinger initiated coverage of Radius Health (RDUS) with a Market Perform rating and $7 price target. The analyst believes management, led by CEO Kelly Martin, is taking the right steps to improve profitability and enhance shareholder value. But Radius' commercial asset Tymlos faces growth uncertainty from competitive pressures, including from Amgen's (AMGN) strong commercialization of Evenity and Prolia, Risinger notes. Over the course of 2022, he expects Radius management to further reduce R&D spending in order to improve cash flow prospects, and looks forward to expected FDA approval of Tymlos for males in December. Longer term, Radius offers significant optionality, including potential value-creation opportunities for elacestrant in the second half of 2023 and pipeline candidate RAD001 in the second half of 2024.

ShowHide Related Items >><<
RDUS Radius Health
$6.25 /

+0.41 (+7.03%)

AMGN Amgen
$247.42 /

+2.48 (+1.01%)

RDUS Radius Health
$6.25 /

+0.41 (+7.03%)

12/23/21 Stifel
New Radius' Tymlos label offers slight expansion potential, says Stifel
12/10/21 Morgan Stanley
Radius Health downgraded to Underweight from Equal Weight at Morgan Stanley
12/09/21 Goldman Sachs
Radius Health downgraded to Neutral from Buy at Goldman Sachs
12/09/21 H.C. Wainwright
Radius Health price target lowered to $10 from $23 at H.C. Wainwright
AMGN Amgen
$247.42 /

+2.48 (+1.01%)

05/23/22 SVB Leerink
Amgen initiated with a Market Perform at SVB Leerink
05/10/22 Mizuho
Amgen price target raised to $208 from $202 at Mizuho
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
04/28/22 BMO Capital
Amgen price target lowered to $243 from $263 at BMO Capital
RDUS Radius Health
$6.25 /

+0.41 (+7.03%)

AMGN Amgen
$247.42 /

+2.48 (+1.01%)

AMGN Amgen
$247.42 /

+2.48 (+1.01%)

RDUS Radius Health
$6.25 /

+0.41 (+7.03%)

AMGN Amgen
$247.42 /

+2.48 (+1.01%)

RDUS Radius Health
$6.25 /

+0.41 (+7.03%)

AMGN Amgen
$247.42 /

+2.48 (+1.01%)

Initiation
Amgen initiated with a Market Perform at SVB Leerink » 06:20
05/23/22
05/23
06:20
05/23/22
06:20
AMGN

Amgen

/

+

SVB Leerink analyst David…

SVB Leerink analyst David Risinger initiated coverage of Amgen with a Market Perform rating and $256 price target. Management is executing well and driving solid near-medium term growth prospects, but the analyst believes the company needs to significantly enhance its pipeline to be able to grow through late decade LOE pressures. The company should benefit from an acceleration in top-line growth in 2023, led by biosimilar Humira, Risinger notes. And its portfolio includes several products that appear set for strong growth over the next several years, including Evenity, Lumakras, Tezspire, Repatha, and Otezla. But at a price-to-earnings of 13.1-times his 2023 EPS, much of this value appears appreciated by investors, the analyst adds.

ShowHide Related Items >><<
AMGN Amgen
/

+

AMGN Amgen
/

+

05/10/22 Mizuho
Amgen price target raised to $208 from $202 at Mizuho
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
04/28/22 BMO Capital
Amgen price target lowered to $243 from $263 at BMO Capital
04/28/22 Piper Sandler
Amgen price target raised to $260 from $255 at Piper Sandler
AMGN Amgen
/

+

AMGN Amgen
/

+

AMGN Amgen
/

+

AMGN Amgen
/

+

Friday
Conference/Events
Cowen biotech analysts to hold an analyst/industry conference call » 14:45
05/20/22
05/20
14:45
05/20/22
14:45
AMGN

Amgen

$245.15 /

+0.21 (+0.09%)

, MRTX

Mirati Therapeutics

$61.03 /

+1.47 (+2.47%)

Biotech Analysts Frahm…

Biotech Analysts Frahm & Werber, along with Dr. Bivona, Professor of Hematology & Oncology at UCSF and Dr. Der, Professor of Molecular Therapeutics at UNC-Chapel Hill, discuss KRAS inhibitors including Amgen's Lumakras and Mirati's Adagrasib and data on KRAS inhibitors to be presented at ASCO on an Analyst/Industry conference call to be held on May 20 at 3 pm. Webcast Link

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$61.03 /

+1.47 (+2.47%)

AMGN Amgen
$245.15 /

+0.21 (+0.09%)

AMGN Amgen
$245.15 /

+0.21 (+0.09%)

05/10/22 Mizuho
Amgen price target raised to $208 from $202 at Mizuho
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
04/28/22 BMO Capital
Amgen price target lowered to $243 from $263 at BMO Capital
04/28/22 Piper Sandler
Amgen price target raised to $260 from $255 at Piper Sandler
MRTX Mirati Therapeutics
$61.03 /

+1.47 (+2.47%)

05/20/22 Guggenheim
Guggenheim upgrades Mirati to Buy on adagrasib's 'highly competitive profile'
05/20/22 Guggenheim
Mirati Therapeutics upgraded to Buy from Neutral at Guggenheim
05/05/22 Citi
Mirati Therapeutics price target lowered to $208 from $227 at Citi
MRTX Mirati Therapeutics
$61.03 /

+1.47 (+2.47%)

AMGN Amgen
$245.15 /

+0.21 (+0.09%)

  • 11
    Nov
AMGN Amgen
$245.15 /

+0.21 (+0.09%)

MRTX Mirati Therapeutics
$61.03 /

+1.47 (+2.47%)

AMGN Amgen
$245.15 /

+0.21 (+0.09%)

AMGN Amgen
$245.15 /

+0.21 (+0.09%)

Hot Stocks
Novartis reports positive CHMP opinion for expanded use of Cosentyx in children » 08:50
05/20/22
05/20
08:50
05/20/22
08:50
NVS

Novartis

$88.66 /

+1.005 (+1.15%)

Novartis announced the…

Novartis announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion for Cosentyx, used alone or in combination with methotrexate, in the juvenile idiopathic arthritis, or JIA, categories of enthesitis-related arthritis and juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. "The positive CHMP opinion reinforces that children and adults living with immunologic rheumatic and dermatological diseases, and the physicians who treat them, may feel confident in the management of these diseases with Cosentyx. We're committed to bringing innovative treatments to young people living with rheumatic diseases across the world. With recent approvals in the US, Japan and Brazil, we are one step closer in our ambition to expand Cosentyx to 10 indications in areas of high unmet need," said Todd Fox, Global Head of Medical Affairs Immunology at Novartis.

ShowHide Related Items >><<
NVS Novartis
$88.66 /

+1.005 (+1.15%)

NVS Novartis
$88.66 /

+1.005 (+1.15%)

05/13/22 Piper Sandler
Point Biopharma price target lowered to $14 from $17 at Piper Sandler
05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
05/09/22 Wolfe Research
Novartis downgraded to Peer Perform from Outperform at Wolfe Research
05/06/22 Morgan Stanley
Novartis price target raised to CHF 94 from CHF 90 at Morgan Stanley
NVS Novartis
$88.66 /

+1.005 (+1.15%)

NVS Novartis
$88.66 /

+1.005 (+1.15%)

NVS Novartis
$88.66 /

+1.005 (+1.15%)

Conference/Events
Cowen biotech analysts to hold an analyst/industry conference call » 04:55
05/20/22
05/20
04:55
05/20/22
04:55
AMGN

Amgen

$244.86 /

+0.94 (+0.39%)

, MRTX

Mirati Therapeutics

$59.59 /

+1.9 (+3.29%)

Biotech Analysts Frahm…

Biotech Analysts Frahm & Werber, along with Dr. Bivona, Professor of Hematology & Oncology at UCSF and Dr. Der, Professor of Molecular Therapeutics at UNC-Chapel Hill, discuss KRAS inhibitors including Amgen's Lumakras and Mirati's Adagrasib and data on KRAS inhibitors to be presented at ASCO on an Analyst/Industry conference call to be held on May 20 at 3 pm. Webcast Link

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$59.59 /

+1.9 (+3.29%)

AMGN Amgen
$244.86 /

+0.94 (+0.39%)

AMGN Amgen
$244.86 /

+0.94 (+0.39%)

05/10/22 Mizuho
Amgen price target raised to $208 from $202 at Mizuho
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
04/28/22 BMO Capital
Amgen price target lowered to $243 from $263 at BMO Capital
04/28/22 Piper Sandler
Amgen price target raised to $260 from $255 at Piper Sandler
MRTX Mirati Therapeutics
$59.59 /

+1.9 (+3.29%)

05/05/22 Citi
Mirati Therapeutics price target lowered to $208 from $227 at Citi
03/02/22 Citi
Mirati Therapeutics price target lowered to $227 from $244 at Citi
03/01/22 BMO Capital
Mirati Therapeutics price target lowered to $130 from $187 at BMO Capital
MRTX Mirati Therapeutics
$59.59 /

+1.9 (+3.29%)

AMGN Amgen
$244.86 /

+0.94 (+0.39%)

  • 11
    Nov
AMGN Amgen
$244.86 /

+0.94 (+0.39%)

MRTX Mirati Therapeutics
$59.59 /

+1.9 (+3.29%)

AMGN Amgen
$244.86 /

+0.94 (+0.39%)

AMGN Amgen
$244.86 /

+0.94 (+0.39%)

Thursday
Conference/Events
Cowen biotech analysts to hold an analyst/industry conference call » 12:21
05/19/22
05/19
12:21
05/19/22
12:21
AMGN

Amgen

$243.20 /

-0.72 (-0.30%)

, MRTX

Mirati Therapeutics

$59.78 /

+2.09 (+3.62%)

Biotech Analysts Frahm…

Biotech Analysts Frahm & Werber, along with Dr. Bivona, Professor of Hematology & Oncology at UCSF and Dr. Der, Professor of Molecular Therapeutics at UNC-Chapel Hill, discuss KRAS inhibitors including Amgen's Lumakras and Mirati's Adagrasib and data on KRAS inhibitors to be presented at ASCO on an Analyst/Industry conference call to be held on May 20 at 3 pm. Webcast Link

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$59.78 /

+2.09 (+3.62%)

AMGN Amgen
$243.20 /

-0.72 (-0.30%)

AMGN Amgen
$243.20 /

-0.72 (-0.30%)

05/10/22 Mizuho
Amgen price target raised to $208 from $202 at Mizuho
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
04/28/22 BMO Capital
Amgen price target lowered to $243 from $263 at BMO Capital
04/28/22 Piper Sandler
Amgen price target raised to $260 from $255 at Piper Sandler
MRTX Mirati Therapeutics
$59.78 /

+2.09 (+3.62%)

05/05/22 Citi
Mirati Therapeutics price target lowered to $208 from $227 at Citi
03/02/22 Citi
Mirati Therapeutics price target lowered to $227 from $244 at Citi
03/01/22 BMO Capital
Mirati Therapeutics price target lowered to $130 from $187 at BMO Capital
MRTX Mirati Therapeutics
$59.78 /

+2.09 (+3.62%)

AMGN Amgen
$243.20 /

-0.72 (-0.30%)

  • 11
    Nov
AMGN Amgen
$243.20 /

-0.72 (-0.30%)

MRTX Mirati Therapeutics
$59.78 /

+2.09 (+3.62%)

AMGN Amgen
$243.20 /

-0.72 (-0.30%)

AMGN Amgen
$243.20 /

-0.72 (-0.30%)

Wednesday
Conference/Events
Amgen management to meet with Oppenheimer » 04:55
05/18/22
05/18
04:55
05/18/22
04:55
AMGN

Amgen

$245.38 /

+1.68 (+0.69%)

Meeting to be held in New…

Meeting to be held in New York on May 18 hosted by Oppenheimer.

ShowHide Related Items >><<
AMGN Amgen
$245.38 /

+1.68 (+0.69%)

AMGN Amgen
$245.38 /

+1.68 (+0.69%)

05/10/22 Mizuho
Amgen price target raised to $208 from $202 at Mizuho
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
04/28/22 BMO Capital
Amgen price target lowered to $243 from $263 at BMO Capital
04/28/22 Piper Sandler
Amgen price target raised to $260 from $255 at Piper Sandler
AMGN Amgen
$245.38 /

+1.68 (+0.69%)

AMGN Amgen
$245.38 /

+1.68 (+0.69%)

AMGN Amgen
$245.38 /

+1.68 (+0.69%)

AMGN Amgen
$245.38 /

+1.68 (+0.69%)

Over a week ago
Recommendations
89bio price target lowered to $19 from $54 at Piper Sandler » 18:54
05/17/22
05/17
18:54
05/17/22
18:54
ETNB

89bio

$2.90 /

+0.255 (+9.66%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi lowered the firm's price target on 89bio to $19 from $54 and keeps an Overweight rating on the shares. The analyst continues to believe that the topline ENTRIGUE SHTG data in Q2 could hit statistical significance and achieve over 30% reduction in TGs, and potentially move the stock up.

ShowHide Related Items >><<
ETNB 89bio
$2.90 /

+0.255 (+9.66%)

ETNB 89bio
$2.90 /

+0.255 (+9.66%)

05/13/22 Oppenheimer
89bio price target lowered to $40 from $49 at Oppenheimer
05/12/22 H.C. Wainwright
89bio price target lowered to $29 from $46 at H.C. Wainwright
05/12/22 Cantor Fitzgerald
89bio price target lowered to $27 from $41 at Cantor Fitzgerald
05/12/22 Raymond James
89bio upgraded to Strong Buy from Outperform at Raymond James
ETNB 89bio
$2.90 /

+0.255 (+9.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.